Adaptive Biotechnologies
ADPT
117 hedge funds and large institutions have $2.5B invested in Adaptive Biotechnologies in 2019 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 45 closing their positions.
58% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $3.02M
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
13% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 45
5% more funds holding
Funds holding: 111 → 117 (+6)
0.62% more ownership
Funds ownership: 64.67% → 65.29% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
33% less capital invested
Capital invested by funds: $3.74B → $2.5B (-$1.24B)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.9M |
| 2 |
BlackRock
New York
|
+$50.5M |
| 3 |
TM
Tiger Management
New York
|
+$45.5M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$26.6M |
| 5 |
FAM
Fred Alger Management
New York
|
+$24M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$21.9M |
| 2 |
Jennison Associates
New York
|
-$13.8M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$12.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.2M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$12M |
ADPT Hedge Fund Activity: Q3 2019 in Review
117 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2019, worth a combined $2.5B — down 33% from $3.74B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ADPT positions and 45 closed out — a net gain of 6 holders — while 31 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $52.9M. The largest seller was Millennium Management, cutting an estimated $21.9M.
- 117 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2019, up from 111 in Q2 2019.
- Funds reported $2.5B of Adaptive Biotechnologies stock for Q3 2019, down 33% quarter-over-quarter.
- 51 funds opened new Adaptive Biotechnologies positions in Q3 2019 and 45 closed out, a net change of +6 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2019 was Vanguard Group, an estimated $52.9M added.
- The largest Adaptive Biotechnologies seller in Q3 2019 was Millennium Management, an estimated $21.9M sold.
Based on aggregated 13F filings for Q3 2019.